Several listed companies in Shanghai and Shenzhen issued important announcements on March 14. The following is a summary of the good news:
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) : approved national export base of traditional Chinese medicine services
The Ministry of Commerce recently released the list of the second batch of national TCM service export bases, and Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) was successfully selected.
Hanwei Electronics Group Corporation(300007) : introduction of war investment Xiaomi Changjiang industry fund by holding subsidiary
Hanwei Electronics Group Corporation(300007) ( Hanwei Electronics Group Corporation(300007) ) it was announced on March 14 that the holding subsidiary Suzhou nengstar Electronic Technology Co., Ltd. plans to increase capital and shares and introduce strategic investor Hubei Xiaomi Changjiang industry fund partnership (limited partnership). Xiaomi Changjiang industry fund plans to increase the capital of Suzhou nengstar with its own capital of 10 million yuan. After the capital increase, it will hold 5.21% equity of Suzhou nengstar.
Sinofibers Technology Co.Ltd(300777) : sign the order contract of carbon fiber and carbon fiber fabric of RMB 2.169 billion
Sinofibers Technology Co.Ltd(300777) ( Sinofibers Technology Co.Ltd(300777) ) announced on March 14 that recently, the company signed a product order contract with customer a, the subject matter of which is carbon fiber and carbon fiber fabric, with a contract amount of RMB 2.169 billion, accounting for 556.94% of the audited operating revenue of the company in the latest fiscal year, and the contract performance period is from 2022 to 2023.
Jiangsu Riying Electronics Co.Ltd(603286) : the actual controller plans to increase the company’s shares by 1% – 2% within 6 months
Jiangsu Riying Electronics Co.Ltd(603286) ( Jiangsu Riying Electronics Co.Ltd(603286) ) announced on March 14 that the actual controller was Rongzhu, who transferred 3.92% of Rihuan investment’s shares, indirectly increased the company’s shares by 0.11%, and planned to increase the company’s shares by 1% – 2% within 6 months.
Ningbo Jintian Copper (Group) Co.Ltd(601609) : it is proposed to repurchase shares with RMB 150300 million
Ningbo Jintian Copper (Group) Co.Ltd(601609) ( Ningbo Jintian Copper (Group) Co.Ltd(601609) ) announced on March 14 that it is planned to repurchase shares with 150 million yuan to 300 million yuan, and the repurchase price shall not exceed 12.65 yuan / share. The shares repurchased this time will be used for equity incentive or employee stock ownership plan.
Winning Health Technology Group Co.Ltd(300253) : it is proposed to repurchase shares with RMB 100 million to RMB 150 million
Winning Health Technology Group Co.Ltd(300253) ( Winning Health Technology Group Co.Ltd(300253) ) announced on March 14 that the company plans to use its own funds to repurchase the company’s shares through centralized bidding. The total amount of funds to be repurchased shall not be less than 100 million yuan and not more than 150 million yuan, and the repurchase price shall not exceed 15 yuan / share. It is intended to be used for the implementation of employee stock ownership plan, equity incentive or the conversion of convertible corporate bonds issued by Listed Companies in the future.
Anshan Hifichem Co.Ltd(300758) : it is proposed to repurchase shares of RMB 100 million to RMB 200 million
Anshan Hifichem Co.Ltd(300758) ( Anshan Hifichem Co.Ltd(300758) ) announced on March 14 that the company plans to buy back the company’s shares by means of centralized bidding transaction with its own funds. The total amount of funds for share repurchase shall not be less than 100 million yuan and not more than 200 million yuan, and the price range of share repurchase shall not exceed 19.60 yuan / share. The repurchased shares will be used for the subsequent implementation of employee stock ownership plan or equity incentive plan.
Ganfeng Lithium Co.Ltd(002460) : the net profit from January to February increased by about 300% year-on-year
Ganfeng Lithium Co.Ltd(002460) ( Ganfeng Lithium Co.Ltd(002460) ) announced on March 14 that according to the preliminary accounting of the company, from January to February 2022, the company achieved an operating revenue of about 3.6 billion yuan, an increase of about 260% year-on-year; The net profit attributable to the shareholders of the listed company was about 1.4 billion yuan, a year-on-year increase of about 300%.
Wuliangye Yibin Co.Ltd(000858) : planning the reconstruction and capacity expansion of new Jiangbei Park
Wuliangye Yibin Co.Ltd(000858) said in the record of investor relations activities that the 8th generation Wuliangye Yibin Co.Ltd(000858) is the cornerstone of the company’s high-end product “two wheel drive”. In 2022, the company will continue to maintain the leading position of the 8th generation brand, absolute market share leading advantage and the leading role of the 1000 yuan price belt. Production project: phase I project of 300000 ton taotan aging wine warehouse; Projects under construction: special grain technology warehouse and milling automation transformation project for brewing, hook storage warehouse project, finished wine packaging and intelligent storage and distribution integration project; Planned new projects: ecological brewing phase I and phase II projects, Jiangbei Park brewing transformation and expansion project, koji making workshop expansion project.
Thalys Medical Technology Group Corporation(603716) : the controlling shareholder intends to introduce strategic investors through agreement transfer
Thalys Medical Technology Group Corporation(603716) ( Thalys Medical Technology Group Corporation(603716) ) on March 14, the company announced that saihai technology, the controlling shareholder, plans to introduce strategic investors and improve the corporate governance structure through agreement transfer; The New Coronavirus antigen detection kit developed by the company has been applied but has not yet obtained the medical device registration certificate issued by the China National Drug Administration, and is not yet available for sale in China.
